INTERLEUKIN-2 REJECTS SPECIAL MEETING

Interleukin-2 Inc. of Alexandria yesterday said it rejected a request by a Canadian firm -- Mandarin Capital Corp. -- to hold a special shareholder meeting because Mandarin does not officially hold Interleukin-2's stock Geert Kersten, Interleukin-2's director of corporate and investor relations, said Mandarin has told the Securities and Exchange Commission it owns 3.25 million shares -- or 14 percent -- of Interleukin-2 stock. Kersten said Mandarin acquired the shares from a major stockholder in exchange for Mandarin stock and stock warrants, plus newly issued five-year notes and debentures.

Because the stock transfer had not been recorded as of yesterday, Interleukin-2 does not regard Mandarin as a stockholder of record and thus denied Mandarin's request for a special stockholder's meeting, Kersten said